Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Primary listing
Industry
Biotechnology
Headquarters
Hellerup, Denmark
Employees
1,017
ISIN
US04351P1012
Website
Ascendis Pharma Metrics
BasicAdvanced
$11B
-
-$6.84
0.40
-
Price and volume
Market cap
$11B
Beta
0.4
52-week high
$183.00
52-week low
$111.09
Average daily volume
420K
Financial strength
Current ratio
1.041
Quick ratio
0.672
Long term debt to equity
-188.25
Total debt to equity
-446.386
Interest coverage (TTM)
-10.08%
Profitability
EBITDA (TTM)
-386.161
Gross margin (TTM)
85.30%
Net profit margin (TTM)
-92.67%
Operating margin (TTM)
-90.54%
Effective tax rate (TTM)
-1.00%
Revenue per employee (TTM)
$422,760
Management effectiveness
Return on assets (TTM)
-22.39%
Return on equity (TTM)
159.67%
Valuation
Price to revenue (TTM)
23.848
Price to book
-55.98
Price to tangible book (TTM)
-54.85
Price to free cash flow (TTM)
-39.811
Free cash flow yield (TTM)
-2.51%
Free cash flow per share (TTM)
-442.04%
Growth
Revenue change (TTM)
12.06%
Earnings per share change (TTM)
-34.42%
3-year revenue growth (CAGR)
198.52%
10-year revenue growth (CAGR)
40.77%
3-year earnings per share growth (CAGR)
-10.19%
10-year earnings per share growth (CAGR)
26.60%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Bulls say / Bears say
Ascendis Pharma's TransCon® CNP has received FDA acceptance for priority review, potentially accelerating its market entry and revenue growth. (ascendispharma.com)
The company reported a significant reduction in net loss for Q1 2025, indicating improved financial health and operational efficiency. (tipranks.com)
Analysts at Evercore ISI have increased the price target for Ascendis Pharma to $280, reflecting strong confidence in the company's growth prospects. (defenseworld.net)
Despite increased revenue, Ascendis Pharma faced higher R&D and administrative expenses in Q1 2025, which could impact profitability. (tipranks.com)
The company's reliance on debt and ongoing profitability issues may pose financial risks and affect investor confidence. (tipranks.com)
While the FDA acceptance of TransCon® CNP is promising, the outcome of the priority review is uncertain, and any negative decision could adversely affect the stock. (ascendispharma.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Ascendis Pharma News
AllArticlesVideos
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
GlobeNewsWire·20 hours ago
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
GlobeNewsWire·4 weeks ago
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $11B as of July 08, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of July 08, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.